Vaginal estrogen and association with dementia: A nationwide population-based study.
Alzheimers Dement
; 18(4): 625-634, 2022 04.
Article
en En
| MEDLINE
| ID: mdl-34322991
ABSTRACT
INTRODUCTION:
Use of systemic hormone therapy has been positively associated with development of dementia. Little is known about the dose-dependent effect of vaginal estradiol on dementia risk.METHODS:
We assessed associations between cumulative dose of vaginal estradiol tablets and dementia in a case-control study nested in a nationwide Danish cohort of women aged 50 to 60 years at study initiation, who did not use systemic hormone therapy. Each case was age-matched to 10 female controls.RESULTS:
A total of 4574 dementia cases were matched to 45,740 controls. Cumulative use of vaginal estradiol tablets was not associated with all-cause dementia; adjusted hazard ratio 1.02 (95% confidence interval [CI] 0.89-1.18) for low dose (< 750 mcg), 1.07 (0.94-1.21) for medium dose (750-2000 mcg), and 0.93 (0.84-1.03) for high dose (> 2000 mcg). Similarly, Alzheimer's disease (AD) only was not associated with vaginal estradiol.DISCUSSION:
Exposure to vaginal estradiol tablets was not associated with all-cause dementia or AD only.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Estradiol
/
Estrógenos
/
Enfermedad de Alzheimer
Tipo de estudio:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
Límite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Alzheimers Dement
Año:
2022
Tipo del documento:
Article
País de afiliación:
Dinamarca